AV Group, which led an FDA-approved pilot to extend testing of the VRS, continues its industry leadership by helping to test industry readiness ahead of this year’s DSCSA deadline.
Travagliato (Brescia), August 22, 2023. Antares Vision Group, an Italian multinational and a leading provider of track and trace and quality control systems, today announced that it has joined the Gateway Certified™ program for Verification Router Service (VRS) verification to help pharmaceutical stakeholders prepare for upcoming serialization and drug product verification requirements in the U.S. Drug Supply Chain Security Act (DSCSA).
The industry established the VRS specifications to help verify the authenticity of products for salable returns. Many providers have developed solutions based on the VRS specification and have voluntarily collaborated in testing to ensure compliance and interoperability.
The Gateway Certified™ program for VRS Verify was established in response to industry concerns that manual methods and self-testing among more than a dozen solution providers was time-consuming, was not scalable, and lacked independent oversight.
Recognizing the importance of connectivity and interoperability, Antares Vision Group, through rfxcel technology, is committed to independent and objective VRS verification testing. “We recognize that solution providers need a more scalable, repeatable, and open testing approach,” said rfxcel CEO Glenn Abood. “We see the limitations of the current approach and see the potential impact on robust, reliable systems as well as adaptation to emerging requirements.”
“We appreciate Antares Vision Group’s leadership and ongoing commitment to facilitate information interoperability and product verification in the pharmaceutical supply chain,” said Gary Lerner, President of Gateway Checker Corporation. “We encourage all solution providers interested in establishing demonstrable VRS conformance to join the Gateway Certified™ program.”
The Gateway Certified™ program provides independent, objective, automated use-case testing to assure that pharmaceutical drug product verification requests and responses consistently meet industry and FDA regulatory requirements. It examines a system’s conformance to requirements and provides objective evidence that it consistently meets industry and regulatory needs.
Herb Wong, rfxcel senior vice president of product and strategy, will be facilitating a Roundtable Discussion about the VRS at the Healthcare Distribution Alliance (HDA) 2023 Traceability Seminar in Washington, D.C. To learn more, click the image below and visit Antares Vision Group at Table-Top 21 at the seminar.
About Antares Vision Group
Antares Vision Group is driving digitalization of products and supply chains by leading traceability, inspection, and integrated data management. AV Group helps companies and institutions to achieve safety, quality, efficiency, and sustainability, enabling Trustparency®.
DIAMIND, AV Group’s integrated ecosystem of solutions, simplifies the technology environment and supports businesses’ growth by enabling a data-driven and tailored journey to digital innovation. Connecting physical products with digital identities, DIAMIND runs at the line, factory, warehouse, enterprise, and supply chain levels, and helps guarantee product quality (inspection systems and equipment) and end-to-end traceability (from raw materials to production, from distribution to the consumer and back) through integrated data management.
AV Group operates in the life science (pharmaceuticals, medical devices, and hospitals), beverage, food, cosmetics, chemicals, and packaging industries and potentially many others.
AV Group has been listed in STAR segment of Euronext since May 2021 and has been included in the Euronext Tech Leaders index, dedicated to leading tech companies with high growth potential, since July 2022.
In 2022, Antares Vision Group recorded a turnover of €223 million. The Group operates in 60 countries, employs more than 1,300 people, and has a consolidated network of over 40 international partners. To learn more, please visit antaresvisiongroup.com and rfxcel.com.
For further information, contact Herb Wong, senior vice president of product and strategy, at hwong@rfxcel.com.
About Gateway Checker Corporation
Gateway Checker™ provides a software as a service platform to facilitate product traceability, DSCSA compliance, and unambiguously verify the interoperability readiness of serialized pharmaceutical transaction records. Drug manufacturers, repackagers, wholesalers, and distributors can quickly and continuously test, validate, and certify adherence to GS1 US Rx EPCIS and VRS product verification application standards.
Gateway Checker is the GS1 US Rx Certified Conformance Testing Service, and is owned and operated by the Gateway Checker Corporation, a wholly owned subsidiary of BrandSure, LLC.
For more information about the Gateway Certified™ program, including VRS System Validation, contact Eran Strod at certified@gatewaychecker.com.
